Gelonghui, January 19 | Junshengtai Pharmaceutical-B (02511.HK) announced that the Group plans to expand its business layout to Hebei Province, China.
Currently, the Group has offices and R&D centers in Shenzhen, Shanghai, Nanchang and Hong Kong. Through the expansion of its business layout in Hebei Province, the Group expects to attract top talents with strong academic backgrounds and industry experience in North China to further strengthen and enrich the Group's industry and regulatory registration resources and/or raw material supply capacity. Possible business expansion measures include the establishment of a new North China cooperative planning, registration management and/or raw material production and operation base.
The above business expansion proposals are also in line with the Group's commitment to further promote strategic cooperation and partnerships in the development, production and/or commercialization of its core drug products in China. The company believes that the above business expansion proposal will enable the Group to make full use of resources in North China.
As of the date of publication of this announcement, the Group is conducting a feasibility study on the above business expansion proposals and actively communicating with the local government and stakeholders the implementation details of the relevant business layout.